State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, reporting beneficial ownership of common stock in Lexeo Therapeutics Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficially owning 3,594,095 shares of Lexeo Therapeutics Inc. common stock.
  • Percent of class: The reported holdings represent 4.4% of the outstanding class of common stock.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote of 3,517,815 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared power to dispose of 3,594,095 shares, with sole dispositive power of 0.
  • Subsidiaries involved: The shares were acquired through subsidiaries identified as SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, each classified as an investment adviser.
  • Triggering event date: The date of event requiring this filing was September 30, 2026.

State Street Corporation's Passive Stake in Lexeo Therapeutics

State Street Corporation, a holding company organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing a 4.4% beneficial ownership position in Lexeo Therapeutics Inc. (CUSIP 52886X107). Lexeo Therapeutics is headquartered at 345 Park Avenue South, 6th Floor, New York, New York 10010, according to the filing. The triggering event date for the filing was September 30, 2026, and the statement was signed on November 9, 2026, by Alok Maheshwary, Senior Vice President.

According to the filing, State Street holds no sole voting power and no sole dispositive power over any of the reported shares. All voting authority covers 3,517,815 shares on a shared basis, while shared dispositive authority extends to the full 3,594,095 shares reported as the aggregate beneficial ownership amount. The filing identifies State Street as a parent holding company, with the relevant subsidiaries listed as SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, all classified as investment advisers.

The filing certifies, in State Street's own words, that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Item 5 of the filing confirms this is a disclosure of ownership of 5 percent or less of the class. Item 6 states "NOT APPLICABLE" with respect to any other person known to have the right to receive dividends or proceeds from the sale of these securities above the 5% threshold.

What Was Disclosed

State Street Corporation reported a 4.4% beneficial ownership position, totaling 3,594,095 shares, in Lexeo Therapeutics Inc. common stock as of September 30, 2026, through three investment adviser subsidiaries, with all voting and dispositive power held on a shared basis.